Tenax Therapeutics Inc (TENX)

Nov 7, 2026

The Rosen Law Firm is reminding investors who purchased Tenax Therapeutics, Inc. (NASDAQ: TENX) securities between November 13, 2023, and August 7, 2026, of an upcoming December 28, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Tenax made materially false and misleading statements regarding the effectiveness and prospects of its drug TNX-103. Investors can join the class action to potentially recover damages without out-of-pocket fees.

Nov 7, 2026

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, has announced an investigation into Tenax Therapeutics, Inc. (TENX) for alleged violations of securities laws. The investigation was prompted by Tenax's announcement that its Phase 3 LEVEL trial of TNX-103 failed to meet its primary and secondary endpoints, leading to an almost 90% drop in share price. SBS is encouraging affected shareholders to join their fraud investigation.

Nov 5, 2026

Tenax Therapeutics reported its financial results for the third quarter of 2026, including a net loss of $16.7 million and cash and cash equivalents of $113.7 million. The company also provided an update on its Phase 3 LEVEL trial for oral levosimendan in PH-HFpEF, noting that while the primary endpoint was not met, statistical analyses identified a predictive enrichment strategy for the ongoing LEVEL-2 trial. Enrollment for LEVEL-2 has been temporarily paused to implement protocol amendments based on these findings, and Tenax has been granted a Type C meeting with the FDA to discuss the development of levosimendan.

Oct 28, 2026

Robbins LLP has reminded investors of a class action lawsuit filed against Tenax Therapeutics, Inc. (NASDAQ: TENX) for allegedly misleading investors regarding the viability of its drug candidate, levosimendan. The lawsuit claims Tenax overstated the clinical, regulatory, and commercial prospects of its PH-HFpEF drug. The stock price significantly dropped after Tenax announced that its Phase 3 trial failed to meet its primary endpoint, leading to substantial losses for investors.

Oct 28, 2026

The Rosen Law Firm announces a class action lawsuit against Tenax Therapeutics, Inc. (NASDAQ: TENX) on behalf of investors who purchased securities between November 13, 2023, and August 7, 2026. The lawsuit alleges that Tenax made false and misleading statements regarding the effectiveness and commercial prospects of its drug TNX-103. Investors have until December 28, 2026, to move the Court to serve as lead plaintiff.

Oct 28, 2026

The Portnoy Law Firm has filed a securities class action lawsuit against Tenax Therapeutics, Inc. (NASDAQ: TENX) on behalf of investors who purchased common stock between November 13, 2023, and August 7, 2026. The lawsuit alleges that Tenax issued false and misleading statements regarding the effectiveness of its drug TNX-103, which failed to meet primary and secondary endpoints in a Phase 3 clinical trial, causing the stock price to plummet. Investors with losses have until December 28, 2026, to seek appointment as lead plaintiff.

Oct 28, 2026

Robbins LLP has filed a class action lawsuit against Tenax Therapeutics, Inc. (NASDAQ: TENX) on behalf of investors who purchased securities between November 13, 2023, and August 7, 2026. The lawsuit alleges that Tenax misled investors about the effectiveness of its drug candidate levosimendan, particularly concerning its Phase 3 LEVEL study for pulmonary hypertension. Tenax's stock price dropped significantly after the company announced that TNX-103 failed to meet its primary and key secondary endpoints in the trial.